Association between the extent of lymph node dissection and severe toxicity in men with prostate cancer treated with post-prostatectomy radiation therapy: results from a large multi-institutional series

Association between the extent of lymph node dissection and severe toxicity in men with prostate cancer treated with post-prostatectomy radiation therapy: results from a large multi-institutional series

Bibliographic Details
Main Authors:	N. Fossati, R.J. Karnes, S. Boorjian, G. Motterle, A. Bossi, E. Mazzone, V. Cucchiara, S. Scuderi, E. Zito, G. Gandaglia, T. Kumar, N. Di Muzio, C. Cozzarini, B.Noris Chiorda, D. Bartkowiak, S. Shariat, G. Goldner, G. Devos, S. Joniau, C. Berghen, G. De Meerleer, H. Van Poppel, F. Montorsi, T. Wiegel, A. Briganti
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320355658

Similar Items

Assessing the impact of salvage radiation therapy field after radical prostatectomy: A long-term analysis from a large multi-institutional series
by: N. Fossati, et al.
Published: (2020-07-01)

Changing patterns and predictors of salvage radiation therapy use over time in patients treated for post-prostatectomy biochemical recurrence: a trend analysis over a 20-year period from a multi institutional series
by: G. Rosiello, et al.
Published: (2020-10-01)

Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: A stage-specific analysis from a large multi-institutional series
by: N. Fossati, et al.
Published: (2020-07-01)

Assessing the impact of salvage radiation therapy field after radical prostatectomy: a long-term analysis from a large multi-institutional series
by: D. Robesti, et al.
Published: (2020-10-01)

Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: a stage-specific analysis from a large multi-institutional series
by: D. Robesti, et al.
Published: (2020-10-01)

Long-term outcomes of clinically node-positive prostate cancer patients treated with radical prostatectomy as part of a multimodal treatment: patterns of recurrence and impact on competing-risk mortality
by: D. Cannoletta, et al.
Published: (2020-10-01)

Radical prostatectomy versus radiotherapy in M1a and low volume M1b prostate cancer patients: an indirect comparison with the STAMPEDE trial arm H
by: G. Gandaglia, et al.
Published: (2020-10-01)

Age and Gleason score upgrading between prostate biopsy and radical prostatectomy. Is this still true in the mp-MRI era?
by: F. Pellegrino, et al.
Published: (2020-10-01)

Are men with low risk prostate cancer but high PIRADS score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
by: A. Stabile, et al.
Published: (2020-07-01)

Multiparametric MRI of the prostate significantly underestimates tumor volume of small visible lesions. Implications for tailored focal therapy approaches
by: A. Stabile, et al.
Published: (2020-07-01)

Patient and region based accuracy of PSMA PET/CT in patients undergoing salvage lymphadenectomy for lymph node recurrence following primary treatment
by: G. Devos, et al.
Published: (2020-07-01)

Are men with low risk prostate cancer but high pirads score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
by: F. Pellegrino, et al.
Published: (2020-10-01)

Should we target all visible areas at mp-MRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
by: A. Stabile, et al.
Published: (2020-07-01)

Should we target all visible areas at mpMRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
by: F. Scalvi, et al.
Published: (2020-10-01)

How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
by: A. Stabile, et al.
Published: (2020-07-01)

Association between BRCA 1/2 polymorphisms and disease aggressiveness in a prospective cohort of prostate cancer patients undergoing radical prostatectomy
by: V. Cucchiara, et al.
Published: (2020-07-01)

When to omit lymphadenectomy during radical prostatectomy in patients with clinical localized prostate cancer: A clinical net benefit analysis weighting staging accuracy, risk of morbidity and life expectancy
by: A. Larcher, et al.
Published: (2020-07-01)

Oncological and functional outcomes of cytoreductive radical prostatectomy (cRP) in men with metastatic hormone-naive prostate cancer (mhnPCA)
by: A. Heidenreich, et al.
Published: (2020-07-01)

How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
by: F. Barletta, et al.
Published: (2020-10-01)

Patterns of clinical recurrences after salvage lymph node dissection for lymph-node recurrent prostate cancer and their impact on oncological outcomes. the importance of patient stratification for tailored post-operative treatments
by: A. Martini, et al.
Published: (2020-10-01)

Persistently elevated prostate-specific antigen after salvage lymph node dissection and its impact on long-term oncological outcomes. the importance of an extensive, multi-modal approach
by: C.A. Bravi, et al.
Published: (2020-10-01)

What is the optimal surgical template for salvage pelvic lymph node dissection in patients with pelvic lymph-node recurrent prostate cancer? results from a large, multi-institutional series
by: C.A. Bravi, et al.
Published: (2020-10-01)

The relative drop of PSA values after androgen deprivation therapy is a useful parameter to select the best candidate for cytoreductive radical prostatectomy among patients with oligometastatic prostate cancer: an external validation study
by: E. Mazzone, et al.
Published: (2020-10-01)

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer
by: Marco Bandini, et al.
Published: (2017-05-01)

The impact of persistently elevated PSA levels on progression and survival of patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer
by: D. Cannoletta, et al.
Published: (2020-10-01)

Association between BRCA 1/2 polymorphisms and disease aggressiveness in a prospective cohort of prostate cancer patients undergoing radical prostatectomy
by: V. Cucchiara, et al.
Published: (2020-10-01)

Multiparametric MRI of the prostate significantly underestimates tumor volume of small visible lesions. Implications for tailored focal therapy approaches
by: F. Barletta, et al.
Published: (2020-10-01)

Metastasis-directed therapy for oligorecurrent prostate cancer: Oncological outcomes of a tertiary referral centre
by: G. Devos, et al.
Published: (2020-07-01)

Persistently elevated prostate-specific antigen after salvage lymph node dissection and its impact on long-term oncological outcomes. The importance of an extensive, multi-modal approach
by: C.A. Bravi, et al.
Published: (2020-07-01)

Patterns of clinical recurrences after salvage lymph node dissection for lymph-node recurrent prostate cancer and their impact on oncological outcomes. The importance of patient stratification for tailored post-operative treatments
by: C.A. Bravi, et al.
Published: (2020-07-01)

The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects
by: Hans Van der Eecken, et al.
Published: (2023-11-01)

Is focal ablation as effective as hemi-ablation? Analysis of treatment patterns over 12 years from a high volume centre for focal therapy
by: A. Stabile, et al.
Published: (2020-07-01)

What is the optimal surgical template for salvage pelvic lymph node dissection in patients with pelvic lymph-node recurrent prostate cancer? Results from a large, multi-institutional series
by: C.A. Bravi, et al.
Published: (2020-07-01)

Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer
by: Carlo A. Bravi, et al.
Published: (2023-01-01)

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy
by: Gaëtan Devos, et al.
Published: (2020-08-01)

Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer
by: Gaëtan Devos, et al.
Published: (2019-09-01)

Is focal ablation as effective as hemi-ablation? analysis of treatment patterns over 12 years from a high volume centre for focal therapy
by: A. Stabile, et al.
Published: (2020-10-01)

Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer
by: Simone Scuderi, et al.
Published: (2023-06-01)

Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended, of Course
by: Giorgio Gandaglia, et al.
Published: (2022-10-01)

Prostate Cancer: Is There Still a Role for Systematic Biopsies? Yes
by: Giorgio Gandaglia, et al.
Published: (2022-04-01)